Use of aryl carbamates in agriculture and other plant-related areas
US-2016353739-A1 · Dec 8, 2016 · US
Pseudomonas aeruginosa bacteriophage Pse-AEP-3 and use thereof for inhibiting proliferation of Pseudomonas aeruginosa
US11457635B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11457635-B2 |
| Application number | US-201816486592-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 11, 2018 |
| Priority date | Feb 17, 2017 |
| Publication date | Oct 4, 2022 |
| Grant date | Oct 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to Podoviridae bacteriophage Pse-AEP-3 (accession number: KCTC 13165BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-3 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-3 as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of suppressing a disease caused by a bacterial strain of Pseudomonas aeruginosa and alleviating the pathological condition of the disease caused by the bacterial strain of Pseudomonas aeruginosa , comprising: administering to an animal other than a human a composition comprising Podoviridae bacteriophage Pse-AEP-3 having a genome set forth by the nucleic acid sequence of SEQ ID NO: 1 and deposited as accession number KCTC 13165BP, which has an ability to specifically kill the bacterial strain of Pseudomonas aeruginosa , and wherein the disease is urinary tract infections, wound infections, bacteremia or endocarditis.
Assignees
Inventors
Classifications
Demonstrated in vivo effect · CPC title
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Viruses; Subviral particles; Bacteriophages · CPC title
Uses of virus other than therapeutic or vaccine, e.g. disinfectant · CPC title
- A01N63/40Primary
Viruses, e.g. bacteriophages · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11457635B2 cover?
- The present invention relates to Podoviridae bacteriophage Pse-AEP-3 (accession number: KCTC 13165BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-3 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing t…
- Who is the assignee on this patent?
- Intron Biotechnology Inc
- What technology area does this patent fall under?
- Primary CPC classification A01N63/40. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).